Skip to content
Cohance Lifesciences logo

Cohance Lifesciences

COHANCE NSE
₹450.45 +10.10 (+2.29%)
P/E
162.03
View as Markdown
MCP
Close 4 Nov 2026 ₹450.45 −273.40 −37.8% 1Y
Start ₹723.85

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
5.81%
Debt to Equity
0.10
EPS (TTM)
₹2.78
Book Value
₹102.23
Market Cap
—
P/E (TTM)
162.03
P/B
4.41
ROE
4.89%
Dividend Yield
1.36%
EBITDA
₹461 Cr
52W High
₹744.30
52W Low
₹266.70
Day Range
₹436.15 – ₹451.75
Volume
2,37,522

Peer Comparison

Healthcare › Pharmaceuticals

Cohance Lifesciences peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Cohance Lifesciences (this company)
₹450.45162.03₹16,972 Cr4.411.36%4.89%5.81%₹2,142 Cr₹58 Cr
Median 8 companies₹1,587.7058.71₹1,25,337 Cr4.590.70%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

37 Weak

Data confidence 100/100

pledge:95%

Category scores

Quality
59
Good
Returns, margins, earnings quality 22% weight
Valuation
36
Poor
Cheap vs sector & own history 24% weight
Growth
2
Poor
Sales & profit trajectory 9% weight
Financial Health
39
Weak
Solvency, leverage, coverage 9% weight
Momentum
37
Weak
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the fundamentals here (pledge>75% ≤ 40).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.6% over last 3 years.
  • Promoters have pledged 94.6% of their holding.
  • Debtor days have increased from 88.0 to 110 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish973
OscillatorsBearish270
Moving AveragesStrong Bearish703

Key readings

RSI (14)
48.30
Neutral
MACD (12,26,9)
0.70
Bearish
SMA (50)
452.21
Bearish
SMA (200)
409.11
Bullish

As of

Analyst Rating

Based on 9 analysts
TIED44%

4 of 9 analysts rate Buy, 1 Hold, 4 Sell.

As of

BUY
4
44%
HOLD
1
11%
SELL
4
44%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+17.57%
3Y+19.19%
1Y−13.00%
TTM−19.75%

Net profit

Net profit growth by window
5Y−16.16%
3Y−28.54%
1Y−69.01%
TTM−87.22%

Operating cash flow

Operating cash flow growth by window
5Y−0.80%
3Y−6.97%
1Y−45.32%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−25.04 pp
3Y−24.02 pp
1Y−11.74 pp
TTM−14.59 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹378 Cr
Mar 2020₹834 Cr
Mar 2021₹1,010 Cr
Mar 2022₹1,320 Cr
Mar 2023₹1,340 Cr
Mar 2024₹1,051 Cr
Mar 2025₹2,608 Cr
Mar 2026₹2,269 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹109 Cr
Mar 2020₹317 Cr
Mar 2021₹362 Cr
Mar 2022₹454 Cr
Mar 2023₹411 Cr
Mar 2024₹300 Cr
Mar 2025₹484 Cr
Mar 2026₹150 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹46.19 Cr +244.7% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 30 Oct 2026
AI opinion · based on fundamentals
Risk high

Cohance Lifesciences Ltd trades at ₹444.3 as of 2026-10-30 with a market cap of ₹16,998.8 Cr. The stock commands a PE of 159.82x on a TTM EPS of ₹2.78, reflecting a sharp 77% decline in TTM profits, while the balance sheet carries a low debt-to-equity of 0.1. The stock is down roughly 43% from its 52-week high of ₹779.45 and promoters have pledged 94.6% of their holding.

Bull Case 7
  • Very low debt-to-equity ratio of 0.1 indicates a conservatively financed balance sheet, providing headroom for future capital deployment or to weather downturns
  • Compounded sales CAGR of 19% over the past 3 years and 18% over 5 years shows a consistent medium-term revenue growth trajectory in the CDMO/pharma space
  • 5-year average ROE of 15% demonstrates the company has historically been capable of generating healthy returns on shareholder equity
  • 3-year average ROE of 11% remains above the cost of equity for many Indian mid-cap pharma companies, suggesting underlying business quality despite recent weakness
  • Stock trading at ₹444.3 is 43% below its 52-week high of ₹779.45 and 67% above its 52-week low of ₹266.7, indicating the stock has recovered meaningfully from its trough
  • Price-to-book ratio of 4.35x paired with low leverage suggests the market still assigns a premium to the asset base, pointing to perceived franchise value in the CDMO segment
  • The healthcare and contract manufacturing sector in India continues to benefit from global supply chain diversification trends, providing a structural tailwind for companies like Cohance
Bear Case 7
  • Promoters have pledged 94.6% of their holding, an extraordinarily high level that creates significant risk of forced selling or loss of control if share price declines further
  • TTM compounded profit growth is -77%, signalling a severe collapse in earnings that has pushed EPS down to just ₹2.78
  • TTM sales growth of -20% indicates a meaningful revenue contraction, reversing the multi-year topline growth trend
  • Last year ROE has fallen to just 5%, and current ROE stands at 3.72%, well below the 3-year average of 11% and 5-year average of 15%, showing rapid deterioration in capital efficiency
  • Debtor days have increased from 88 to 110 days, suggesting deteriorating working capital discipline and potential collection issues with customers
  • Despite reporting profits, the company has not been paying dividends — combined with a stated dividend yield of 1.25%, any payout appears minimal relative to what retained earnings and shareholders may warrant
  • Stock CAGR of -49% over 1 year and -8% over 3 years reflects sustained wealth destruction for investors across multiple time horizons

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Cohance Lifesciences is making steady governance moves with a credible ESG rating and a formally approved leadership appointment. No headwinds are visible in the recent news cycle. The independent 'Strong' ESG rating is a modest positive for institutional investor interest. The outlook is stable, with the leadership transition timeline extending into late 2026.

Positives 1
  • Strong ESG rating received Oct 6

    Cohance Lifesciences received a voluntary ESG rating of 'Strong' through an independent assessment. The company did not commission or engage the rating agency for this evaluation, lending credibility to the outcome.

Neutral 1
  • CEO appointment gets govt nod Oct 12

    The Ministry of Corporate Affairs approved Umang Vohra's appointment as Chairman and Group CEO of Cohance Lifesciences, effective October 8, 2026.

Quarterly Results

₹ Cr
COHANCE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
348
231
220
253
488
604
676
840
549
556
545
619
422
Expenses
181
133
154
180
363
398
439
611
437
435
449
520
421
Operating Profit
167
98
66
73
125
205
237
229
112
121
95
99
1
OPM %
48%
42%
30%
29%
26%
34%
35%
27%
20%
22%
18%
16%
0.3%
Other Income
11
20
14
17
18.16
16
15.71
−4
6
16
1
−18
12
Interest
1
0
1.27
2
10
10
3.33
10
10
9
9
9
7
Depreciation
13
12
13
17
31
38
44
54
45
44
47
51
50
PBT
164
105
65
71
103
174
205
161
63
84
41
20
−43
Tax %
26%
25%
29%
25%
27%
21%
25%
27%
26%
21%
29%
58%
5%
Net Profit
121
80
47
53
75
138
153
117
46
66
29
8
−45
EPS (₹)
4.74
3.13
1.84
2.1
2.96
5.44
6.01
4.73
1.28
1.94
0.96
0.51
−0.63

Profit & Loss

₹ Cr
COHANCE profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
378
834
1,010
1,320
1,340
1,051
2,608
2,269
2,142
Expenses
206
449
567
738
766
645
1,811
1,841
1,825
Operating Profit
172
385
443
582
574
406
797
427
316
OPM %
45%
46%
44%
44%
43%
39%
31%
19%
15%
Other Income
1
66
68
133
46
62
53
4
11
Interest
3
23
12
9
13
7
41
37
34
Depreciation
12
24
32
39
48
55
167
187
192
PBT
158
405
468
668
560
406
643
207
101
Tax %
31%
22%
23%
32%
27%
26%
25%
27%
—
Net Profit
109
317
362
454
411
300
484
150
59
EPS (₹)
—
12.45
14.23
17.83
16.16
11.8
19.14
4.68
2.78
Div. Payout %
0%
20%
14%
28%
37%
0%
0%
0%
—

Balance Sheet

₹ Cr
COHANCE balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0
13
25
25
25
25
25
38
Reserves
578
832
1,155
1,502
1,710
2,025
3,623
3,873
Borrowings
83
186
143
97
70
65
486
400
Other Liabilities
123
142
151
205
160
138
1,346
1,415
Total Liabilities
783
1,173
1,474
1,830
1,966
2,254
5,480
5,727
Fixed Assets
271
357
441
534
663
670
3,107
3,369
CWIP
111
102
96
30
165
179
334
178
Investments
7
338
542
598
536
904
337
529
Other Assets
394
376
395
667
601
501
1,702
1,652
Total Assets
783
1,173
1,474
1,830
1,966
2,254
5,480
5,727

Cash Flow

₹ Cr
COHANCE cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
50
407
383
330
457
358
673
368
Investing
−65
−413
−311
−136
−195
−362
−388
−251
Financing
26
7
−76
−156
−242
−14
−327
−165
Net Cash Flow
11
1
−5
37
20
−18
−42
−48
Free Cash Flow
−6
304
272
255
171
307
357
169
CFO/EBITDA
49
128
111
88
105
115
107
102

Ratios

COHANCE financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
142
51
37
65
30
46
108
110
Inventory Days
556
278
243
259
279
268
209
310
Days Payable
190
113
100
97
63
49
120
157
Cash Conversion Cycle
509
217
180
228
247
265
197
263
Working Capital Days
205
64
56
108
99
115
106
133
ROCE %
—
50%
40%
41%
32%
19%
21%
6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Cohance Lifesciences insights

71 extracted metrics across FY19–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 57.48%
  • DIIs 18.86%
  • Others 8.46%
  • FIIs 7.71%
  • Public 7.50%

94.56% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Cohance Lifesciences

What does Cohance Lifesciences Ltd do?
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals.
Where is Cohance Lifesciences Ltd (COHANCE) listed?
Cohance Lifesciences Ltd trades as COHANCE on the NSE and under code 543064 on the BSE.
Which sector does Cohance Lifesciences Ltd belong to?
Cohance Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd trades at a PE ratio of 162.03 as of 4 Nov 2026, on earnings per share of ₹2.78, against a book value of ₹102.23 per share.
What is the 52-week high and low of Cohance Lifesciences Ltd?
Over the last 52 weeks Cohance Lifesciences Ltd has traded between ₹266.7 and ₹744.3 as of 4 Nov 2026.
Does Cohance Lifesciences Ltd pay dividends?
Cohance Lifesciences Ltd has a dividend yield of 1.36%.
What is the Return on Equity (ROE) of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd reported a return on equity of 4.89%. Its debt-to-equity ratio is 0.10.

Company Information

Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.

Website cohance.com
CEO Mr. Vivek Sharma CPA
Employees 1,212
Listed 9 Mar 2020
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/COHANCE.md for Cohance Lifesciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month